Complete remission after treatment with single-agent ofatumumab in a patient with high-risk leukemic mantle-cell lymphoma

Journal of Clinical Oncology

Volumn 31, Issue 19, 2013, Pages

  Hunstig, Friederike ^a   Hammersen, Jakob ^a   Kunert, Christa ^a   Petersen, Iver ^a   Merz, Hartmut ^b   Glaser, Anita ^a   Teichgräber, Ulf ^a   Hochhaus, Andreas ^a   La Rosée, Paul ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; CD19 ANTIGEN; CD23 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DEXAMETHASONE; IMMUNOGLOBULIN; INTERLEUKIN 2 RECEPTOR ALPHA; KI 67 ANTIGEN; MITOXANTRONE; OFATUMUMAB; PREDNISOLONE; PREDNISONE; RITUXIMAB; TEMSIROLIMUS; VINCRISTINE; ANTINEOPLASTIC AGENT; CD20 ANTIGEN; IGH CCND1 FUSION PROTEIN, HUMAN; IGH-CCND1 FUSION PROTEIN, HUMAN; MONOCLONAL ANTIBODY; ONCOPROTEIN; TUMOR MARKER;

ACUTE LEUKEMIA; AGED; ARTICLE; B LYMPHOCYTE; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CASE REPORT; CCND1 GENE; CHROMOSOME 13; CHROMOSOME 17; CHROMOSOME 17P; CHROMOSOME ANALYSIS; CHRONIC SINUSITIS; COLITIS; COMPUTER ASSISTED TOMOGRAPHY; CYTOKINE RELEASE SYNDROME; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERYTHRODERMA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE PROBE; GENE REARRANGEMENT; HEART ATRIUM FIBRILLATION; HEART DISEASE; HIP ARTHROPLASTY; HOSPITALIZATION; HUMAN; HYPERTENSION; IGH GENE; IMMUNOGLOBULIN DEFICIENCY; INFUSION RELATED REACTION; KNEE ARTHROPLASTY; LEUKOCYTE COUNT; LEUKOCYTE DIFFERENTIAL COUNT; LYMPHOCYTE COUNT; LYMPHOCYTOSIS; MANTLE CELL LYMPHOMA; MANTLE CELL LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX; MEDICAL HISTORY; METAPHASE; MULTIPLE CYCLE TREATMENT; NEUTROPHIL COUNT; NIGHT SWEAT; OBESITY; PHYSICAL EXAMINATION; PNEUMONIA; PRIORITY JOURNAL; SINUSITIS; SKIN TOXICITY; SPLEEN SIZE; SPLENOMEGALY; SPONDYLOSIS; TREATMENT RESPONSE; WEIGHT REDUCTION; Y CHROMOSOME; DRUG EFFECT; FLOW CYTOMETRY; GENETICS; INDUCTION CHEMOTHERAPY; MALE; METHODOLOGY; MOLECULARLY TARGETED THERAPY; PATHOLOGY; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; FLOW CYTOMETRY; HUMANS; INDUCTION CHEMOTHERAPY; LYMPHOMA, MANTLE-CELL; MALE; MOLECULAR TARGETED THERAPY; ONCOGENE PROTEINS, FUSION; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84883105927     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.9438     Document Type: Article

References (20)

1. Perez-Galan P, Dreyling M, Wiestner A: Mantle cell lymphoma: Biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 117:26-38, 2011
2. Jares P, Colomer D, Campo E: Genetic and molecular pathogenesis of mantle cell lymphoma: Perspectives for new targeted therapeutics. Nat Rev Cancer 7:750-762, 2007
3. Fernandez V, Salamero O, Espinet B, et al: Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 70:1408-1418, 2010
4. Rosenwald A, Wright G, Wiestner A, et al: The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 3:185-197, 2003
5. Dreyling M, Lenz G, Hoster E, et al: Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: Results of a prospective randomized trial of the European MCL Network. Blood 105:2677-2684, 2005
6. Hess G, Herbrecht R, Romaguera J, et al: Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 27:3822-3829, 2009
7. O'Connor OA, Wright J, Moskowitz C, et al: Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 23:676-684, 2005
8. Dreyling M, Kluin-Nelemans HC, Beà S, et al: Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: Report of the 10th annual conference of the European Mantle Cell Lymphoma Network. Leuk Lymphoma 52:2226-2236, 2011
9. Todorovic M, Balint B, Andjelic B, et al: Outcome prediction of advanced mantle cell lymphoma by international prognostic index versus different mantle cell lymphoma indexes: One institution study. Med Oncol 29:2212-2219, 2012
10. Herold M, Schulze A, Niederwieser D, et al: Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: Results of a randomised phase III trial (OSHO# 19). J Cancer Res Clin Oncol 132:105-112, 2006
11. Herold M, Haas A, Srock S, et al: Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group Hematology and Oncology Study. J Clin Oncol 25:1986-1992, 2007
12. Wierda WG, Kipps Tj, Mayer J, et al: Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 28:1749-1755, 2010
13. Navarro A, Campo E II: New perspectives and challenges in the understanding of mantle cell lymphoma Ann Oncol 22:p. iv32-iv35, 2011
14. Magni M, Di Nicola M, Carlo-Stella C, et al: Safety, tolerability and activity of ofatumumab, bendamustine and dexamethasone combination as first-line treatment of mantle-cell lymphoma in the elderly: A multicenter study. Blood 118:716, 2011 (abstr 1647)
15. Foran JM, Rohatner AZ, Cunningham D, et al: European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 18:317-324, 2000
16. Teeling JL, Mackus WJ, Wiegman LJ, et al: The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 177:362-371, 2006
17. Teeling JL, French RR, Cragg MS, et al: Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104:1793-1800, 2004
18. Coiffier B, Lepretre S, Pedersen LM, et al: Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: A phase 1-2 study. Blood 111:1094-1100, 2008
19. Cheson BD: Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J Clin Oncol 28:3525-3530, 2010
20. Fowler NH, Kahanic SP, Forero A, et al: Results of a phase II study with bendamustine and ofatumumab in untreated indolent B-cell non-Hodgkin's lymphoma. Blood 118:353, 2011 (abstr 778)